Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence J Le Noury, JM Nardo, D Healy, J Jureidini, M Raven, C Tufanaru, ... Bmj 351, 2015 | 379 | 2015 |
The increased use of antidepressants has contributed to the worldwide reduction in suicide rates G Isacsson, CL Rich, J Jureidini, M Raven The British Journal of Psychiatry 196 (6), 429-433, 2010 | 102 | 2010 |
Addiction: Not just brain malfunction. D Heim Nature 507 (7490), 2014 | 89 | 2014 |
Mental health messages in prominent mental health apps L Parker, L Bero, D Gillies, M Raven, B Mintzes, J Jureidini, Q Grundy The Annals of Family Medicine 16 (4), 338-342, 2018 | 70 | 2018 |
Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: systematic review. M Whitely, M Raven, S Timimi, J Jureidini, J Phillimore, J Leo, J Moncrieff, ... Journal of Child Psychology and Psychiatry, 2018 | 69 | 2018 |
A health app developer’s guide to law and policy: a multi-sector policy analysis L Parker, T Karliychuk, D Gillies, B Mintzes, M Raven, Q & Grundy BMC Medical Informatics and Decision Making 17 (141), 2017 | 64 | 2017 |
Dimensions of control in bulimia and anorexia nervosa: Internal control, desire for control, or fear of losing self-control? M Tiggemann, M Raven Eating Disorders 6 (1), 65-71, 1998 | 54 | 1998 |
Video-based telehealth in Australian primary health care: current use and future potential M Raven, C Butler, P Bywood Australian Journal of Primary Health 19 (4), 283-286, 2013 | 52 | 2013 |
The" Hot potato" of mental health app regulation: a critical case study of the australian policy arena L Parker, L Bero, D Gillies, M Raven, Q Grundy International journal of health policy and management 8 (3), 168, 2019 | 37 | 2019 |
Antidepressant prescribing and suicide/self-harm by young Australians: regulatory warnings, contradictory advice, and long-term trends M Whitely, M Raven, J Jureidini Frontiers in psychiatry 11, 478, 2020 | 28 | 2020 |
Trends in prescription of psychotropic medications to children and adolescents in Australian primary care from 2011 to 2018 J Klau, CDO Bernardo, DA Gonzalez-Chica, M Raven, J Jureidini Australian & New Zealand Journal of Psychiatry 56 (11), 1477-1490, 2022 | 27 | 2022 |
Psychotropic marketing practices and problems: Implications for DSM-5 M Raven, P Parry The Journal of nervous and mental disease 200 (6), 512-516, 2012 | 25 | 2012 |
Drinkers, non‐drinkers and deferrers: Reconsidering the beer/footy couplet amongst Australian Rules football fans1 K Thompson, C Palmer, M Raven The Australian Journal of Anthropology 22 (3), 388-408, 2011 | 25 | 2011 |
Study 329 continuation phase: safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression J Le Noury, JM Nardo, D Healy, J Jureidini, M Raven, C Tufanaru, ... International Journal of Risk & Safety in Medicine 28 (3), 143-161, 2016 | 18 | 2016 |
Improving the integration of mental health services in primary health care at the macro level P Bywood, L Brown, M Raven Adelaide: Primary Health Care Research and Information Service, 2015 | 18 | 2015 |
Novel melatonin-based treatments for major depression J Jureidini, M Raven The Lancet 379 (9812), 216-217, 2012 | 16 | 2012 |
Current'best practice'interventions for gambling problems: A theoretical and empirical review J O’Connor, R Ashenden, M Raven, S Allsop Melbourne: Department of Human Services, 2000 | 16 | 2000 |
‘Prodromal’diagnosis of psychosis: ethical problems in research and clinical practice M Raven, GW Stuart, J Jureidini Australian & New Zealand Journal of Psychiatry 46 (1), 64-65, 2012 | 15 | 2012 |
Health of grey nomads: On the move and under the health sector radar M Raven Australian Journal of Rural Health 24 (3), 182-187, 2016 | 14 | 2016 |
Does direct-to-consumer advertising of antidepressants lead to a net social benefit? J Jureidini, B Mintzes, M Raven Pharmacoeconomics 26, 557-566, 2008 | 14 | 2008 |